A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept.
Cummins
Carole
C
West Midlands Health Technology Assessment Group, Institute of Child Health, University of Birmingham, Birmingham, UK.
Connock
M
M
Fry-Smith
A
A
Burls
A
A
D000293:Adolescent; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D017281:Cost of Illness; D016527:Drug Costs; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use*; D019057:Quality-Adjusted Life Years; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use*; D013222:State Medicine; D016896:Treatment Outcome; D006113:United Kingdom
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept